7-Oxopyrrolopyridine-derived DPP4 inhibitors-mitigation of CYP and hERG liabilities via introduction of polar functionalities in the active site.
Wang, W., Devasthale, P., Wang, A., Harrity, T., Egan, D., Morgan, N., Cap, M., Fura, A., Klei, H.E., Kish, K., Weigelt, C., Sun, L., Levesque, P., Li, Y.X., Zahler, R., Kirby, M.S., Hamann, L.G.(2011) Bioorg Med Chem Lett 21: 6646-6651
- PubMed: 21996520 
- DOI: https://doi.org/10.1016/j.bmcl.2011.09.074
- Primary Citation of Related Structures:  
3SWW, 3SX4 - PubMed Abstract: 
Design, synthesis, and SAR of 7-oxopyrrolopyridine-derived DPP4 inhibitors are described. The preferred stereochemistry of these atropisomeric biaryl analogs has been identified as Sa. Compound (+)-3t, with a K(i) against DPP4, DPP8, and DPP9 of 0.37 nM, 2.2, and 5.7 μM, respectively, showed a significant improvement in insulin response after single doses of 3 and 10 μmol/kg in ob/ob mice.
Organizational Affiliation: 
Metabolic Diseases Chemistry, Bristol-Myers Squibb Research and Development, Princeton, NJ 08543-5400, USA.